<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="38585">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02016222</url>
  </required_header>
  <id_info>
    <org_study_id>RC-P0006</org_study_id>
    <nct_id>NCT02016222</nct_id>
  </id_info>
  <brief_title>Tear Analysis in the Diagnosis of Multiple Sclerosis</brief_title>
  <acronym>LARMES</acronym>
  <official_title>Tear Analysis in the Diagnosis of Primary Progressive Forms of Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lille Catholic University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lille Catholic University</source>
  <oversight_info>
    <authority>France: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the primary progressive multiple sclerosis, the detection of oligoclonal bands in
      cerebrospinal fluid is critical for the diagnosis. However, lumbar puncture for
      cerebrospinal fluid collection is considered relatively invasive. Our hypothesis is that
      oligoclonal bands detection in tears is possible and useful for the diagnosis of multiple
      sclerosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the present study is to assess concordance between oligoclonal bands
      detection in tears and in cerebrospinal fluid. We will include patients with primary
      progressive multiple sclerosis and we will compare results of oligoclonal bands detection by
      isoelectric focusing in cerebrospinal fluid and tears. Tears will be collected using a
      Schirmer strip. This would circumvent the practice of invasive lumbar punctures currently
      used in multiple sclerosis diagnosis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Concordance between the quantification of oligoclonal IgG bands by isoelectric focusing in tears and in the cerebrospinal fluid in patients with primary progressive multiple sclerosis</measure>
    <time_frame>at baseline and two years after (+/- 2 months)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Isoelectrophoretic profile of tears</measure>
    <time_frame>Baseline and two years after inclusion</time_frame>
    <safety_issue>No</safety_issue>
    <description>Determination of the stability and prognostic value of isoelectrophoretic profile of tears at inclusion, after 2 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Isoelectrophoretic profiles of tears by digital recording and analysis of images</measure>
    <time_frame>Baseline  and two years after</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Primary Progressive Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Tears sampling</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>tears sampling</intervention_name>
    <arm_group_label>Tears sampling</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years old or more

          -  Progressive neurological deficit after 12 months

          -  At least 9 T2 brain lesions of minimum 3 mm evidenced by MRI and/or four or more T2
             lesions of minimum 3 mm with positive Visual Evoked Potential and/or positive spinal
             cord MRI (at least two focal T2 lesions)

        Exclusion Criteria:

          -  Asiatic persons

          -  recurrent forms of the disease

          -  Persons wearing contact lenses

          -  Ocular Infection

          -  Corticoid treatment at least 30 days before sampling

          -  immunosuppressive  or immunomodulatory treatment 3 months before sampling
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Hautecoeur, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupement des Hôpitaux de l'Institut Catholique de Lille (GHICL)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elisabeth Baumelou, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Groupement des Hôpitaux de l'Institut Catholique de Lille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrick Vermersch, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Régional Universitaire de Lille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christine Lebrun-Frenay, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nice</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jérome De Sèze, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Régional Universitaire de Strasbourg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thibaut Moreau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Dijon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre Clavelou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Régional Universitaire de Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olivier Heinzlef, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre hospitalier intercommunal de Poissy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian Confavreux, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc Debouverie, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central Hospital, Nancy, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean Pelletier, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>L'assistance Publique des Hôpitaux de Marseille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruno Brochet, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gilles Defer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Caen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Thouvenot, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nîmes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ibrahima Diop, CTC</last_name>
    <phone>+33 3 20 22 57 34</phone>
    <email>diop.ibrahima@ghicl.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gabriela Certad, MD, PhD</last_name>
    <phone>+33 3 20 22 57 34</phone>
    <email>certad.gabriela@ghicl.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre hospitalier universitaire (CHU), Nice</name>
      <address>
        <city>Nice</city>
        <state>Alpes Maritimes</state>
        <zip>06003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christine Lebrun-Frenay, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupement des Hôpitaux de l'Institut Catholique de Lille (GHICL)</name>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Patrick Hautecoeur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gauthier Calais., MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arnaud Kwiatkowski., MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitaliere universitaire</name>
      <address>
        <city>Bordeaux</city>
        <zip>33404</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bruno Brochet, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gilles Defer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier régional universitaire</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pierre Clavelou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thibault Moreau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier régional universitaire</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Patrick Vermersch, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospices civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69229</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christian Confavreux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Assistance Publique - Hôpitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean Pelletier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire</name>
      <address>
        <city>Nancy</city>
        <zip>54035</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marc Debouverie, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire</name>
      <address>
        <city>Nimes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eric Thouvenot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier intercommunal</name>
      <address>
        <city>Poissy</city>
        <zip>78303</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Olivier Heinzlef, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier régional universtaire</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jérôme De Seze, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 18, 2013</lastchanged_date>
  <firstreceived_date>November 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>primary progressive multiple sclerosis</keyword>
  <keyword>diagnosis</keyword>
  <keyword>tears</keyword>
  <keyword>isoelectric focusing</keyword>
  <keyword>oligoclonal bands</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
